JPM advised Dr.Max on the acquisition of a leading pharmacy chain in Serbia

JPM advised Dr.Max on the acquisition of a leading pharmacy chain in Serbia

JPM recently advised Dr. Max Group, a group member of Penta Investment Group, the largest pharmacy network in Central and Eastern Europe, on its acquisition of Farmanea and Farmakop, one of the leading pharmacy chains in Serbia.

Dr. Max Group, via its local subsidiary AsterFarm doo, has acquired full ownership and control over Farmanea and Farmakop. Dr. Max is one of the biggest pharmacy chains in the CEE, the market leader in Czechia and Slovakia, and one of the biggest pharmacy chains in Poland. It operates almost 1000 pharmacies and serves more than 210,000 customers daily.

JPM also advised Dr. Max Group during the merger control procedure before the Serbian competition authority regarding the acquisition of sole control over Farmanea and Farmakop, which were unconditionally approved by the Commission for Protection of Competition.

JPM Partners Jelena Stanković and Nikola Poznanovic have led the JPM team in advising on M&A transaction, while Partner Nikola Poznanovic has represented Dr. Max Group during merger approval procedures before the Commission for Protection of Competition.